Chester County News and Community Website
WILMINGTON, DE — The Phase III MATTERHORN trial has delivered groundbreaking results, demonstrating that AstraZeneca’s IMFINZI® (durvalumab) combined with FLOT chemotherapy significantly improves outcomes for patients with resectable early-stage and …
MATTERHORN Trial Reveals Promising Results for Early Gastric Cancer Treatment Read More WILMINGTON, DE — Groundbreaking results from AstraZeneca’s Phase III SERENA-6 trial reveal a significant leap forward in the treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The trial demonstrated …
AstraZeneca’s SERENA-6 Trial Marks Breakthrough in Breast Cancer Treatment Read MoreWAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis (AD). This randomized, …
Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment Read More
PHILADELPHIA, PA — Vittoria Biotherapeutics Inc. has announced its upcoming presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The trials-in-progress poster will spotlight …
Vittoria Biotherapeutics to Present VIPER-101 Phase 1 Trial at 2025 ASCO Annual Meeting Read More WILMINGTON, DE — AstraZeneca has announced groundbreaking results from the BATURA Phase IIIb trial for AIRSUPRA (albuterol/budesonide), marking a significant advancement in asthma care. The anti-inflammatory rescue therapy demonstrated substantial …
AstraZeneca’s BATURA Trial Highlights Breakthrough Results for Asthma Treatment Read More
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) unveiled significant findings from its Phase 3 IMPALA-2 clinical trial of molgramostim during two poster presentations at the ATS International Conference 2025. The …
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced detailed results from its pivotal Phase 3 Launch-HTN trial, showcasing the efficacy and safety of lorundrostat for patients with uncontrolled …
Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has unveiled new data on istaroxime, a treatment candidate for cardiogenic shock, at the European Society of Cardiology Heart Failure 2025 Conference …
Windtree Showcases Promising Istaroxime Data for Cardiogenic Shock at Major Conference Read More
WILMINGTON, DE — A new treatment option has emerged for patients battling advanced squamous cell carcinoma of the anal canal (SCAC). The U.S. Food and Drug Administration (FDA) has approved …
FDA Approves Zynyz for Advanced Anal Cancer, Offering New Hope for Patients Read More
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) reported notable progress in Q1 2025, emphasizing advancements in its clinical and preclinical iPSC-derived cell therapy programs. Highlights include updates on the …
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline Read More